Cell Impact AB (Nasdaq First North GM: CI) reports the following summary for the first quarter 2023.

The annual general meeting of Cell Impact AB (publ) was held on 20 April 2023.

Cell Impact AB (publ) announces the nomination committee's proposals for board members and board renumeration ahead of the annual general meeting which will be held on 20 April 2023.

Cell Impact AB (publ) has now published the annual report for 2022 on its website: www.cellimpact.com.

The shareholders of Cell Impact AB (publ), reg. no. 556576-6655, are hereby invited to participate in the annual general meeting to be held on Thursday 20 April 2023, 14.00 hours (CET), at the premises of Cell Impact AB (publ) on Källmossvägen 7A in Karlskoga, Sweden. Registration from 13.30 hours (CET).

Cell Impact AB (Nasdaq First North GM: CI) reports the following summary for the fourth quarter.

The need for green technology that can solve the climate crisis has increased sharply. This applies in particular to the demand for hydrogen technology. This has made Cell Impact, a global supplier of a key component for fuel cells, one of the fastest growing companies in Sweden.

Cell Impact AB (Nasdaq First North GM: CI) reports the following financial summary for the third quarter.

Cell Impact AB (Nasdaq First North GM: CI) will set up a Cell Impact Forming™ flow plate demonstration line in Japan in collaboration with leading Japanese auto parts supplier F.C.C. Co., Ltd.

Cell Impact AB (Nasdaq First North GM: CI) reports the following financial summary for the second quarter.

Cell Impact AB's (Nasdaq First North GM: CI) wholly owned subsidiary Cell Impact Japan Inc. has received an order worth MSEK 1.6. The order is for a flow plate design project and involves flow plate prototype production. It is a continuation of earlier established activities in Japan and will be delivered during the third quarter of 2022.

The Annual General Meeting of Cell Impact AB (publ) ("Cell Impact" or the "Company") on April 21, 2022 resolved, in accordance with the boards of director's proposal, on amendments of Cell Impact's articles of association including the removal of the class A share. The Company's class B shares will therefore be ordinary shares. The share's voting value has also been changed from 1/10 vote per share to 1 vote per share.

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the first quarter.

Cell Impact AB (Nasdaq First North GM: CI B) announces that the local IF Metall union club at Cell Impact has elected Lillette Hallblad as employee representative to Cell Impact's Board of Directors.

The annual general meeting of Cell Impact AB (Nasdaq First North GM: CI B) was held on April 21, 2022.

The shareholders of Cell Impact AB (publ) (Nasdaq First North GM: CI B), reg. no. 556576-6655, are hereby invited to participate in the annual general meeting to be held on Thursday 21 April 2022, 14.00 hours (CET), at the premises of the Royal Swedish Academy of Engineering Sciences (IVA Konferenscenter), Grev Turegatan 16, Stockholm, Sweden. Registration from 13:15 hours (CET).

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the fourth quarter.

On December 23, 2021, Cell Impact AB (publ) (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") announced that the preliminary outcome for the rights issue (the "Rights Issue"), for which the subscription period ended on December 23, 2021, indicated that the Rights Issue was oversubscribed, which has now been confirmed by the final outcome. Thus, no guarantee commitments will be utilized. The Rights Issue will provide the Company with approximately SEK 349 million before deduction of transaction costs related to the Rights Issue.

Cell Impact AB (publ) (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") announces that the preliminary outcome for the rights issue (the "Rights Issue"), for which the subscription period ended on December 23, 2021, indicates that the Rights Issue is oversubscribed and that no guarantee commitments will need to be utilized. The Rights Issue will provide the Company with approximately SEK 349 million before deduction of transaction costs related to the Rights Issue.

Cell Impact AB's (Nasdaq First North Growth Market: CI B, "Cell Impact" or the "Company") prospectus related to the rights issue has today, December 6, 2021, been approved and registered by the Swedish Financial Supervisory Authority and is available on Cell Impact's website, www.cellimpact.com, and on Carnegie Investment Bank AB's (publ) website, www.carnegie.se, and will be made available on the Swedish Financial Supervisory Authority's website, www.fi.se.

The Board of Directors in Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") has today, pursuant to the authorization granted by the extra general meeting on November 16, 2021, resolved on a fully guaranteed rights issue of up to 16,812,094 series B shares with preferential right for the Company's existing shareholders (the "Rights Issue"). The subscription price in the Rights Issue is SEK 20.75 per series B share. If the Rights Issue is fully subscribed, the Company will receive approximately SEK 349 million before deduction of transaction costs related to the Rights Issue.

Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") today announces an updated indicative timetable for the fully guaranteed Rights Issue. The updated indicative timetable deviates from the previously communicated indicative timetable due to a postponed prospectus approval as a result of high workload for the Swedish Financial Supervisory Authority's prospectus unit.

An extraordinary general meeting of Cell Impact AB (publ) was held on 16 November 2021 whereby the shareholders, inter alia, authorized the board of directors to resolve upon issue of shares, warrants and/or convertibles.

The shareholders of Cell Impact AB (publ), reg. no. 556576-6655, are hereby invited to participate in an extraordinary general meeting on Tuesday 16 November 2021.

The Board of Directors in Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") today announces its intention to resolve on a fully guaranteed rights issue of series B shares of up to approximately SEK 350 million (the "Rights Issue"). An Extra General Meeting is proposed to authorize the Board of Directors to resolve on the Rights Issue. The Extra General Meeting intends to be held on November 16, 2021 and the notice will be announced through a separate press release. The purpose of the Rights Issue is to ensure continued financing of Cell Impact's business plan, which includes increasing the Company's production capacity. Together with existing cash, the net proceeds from the Rights Issue is expected to be sufficient to finance the Company's business plan to mid-2023 provided that the Rights Issue generates gross proceeds of approximately SEK 350 million.

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the third quarter.

Cell Impact AB (Nasdaq First North GM: Cell Impact AB (Nasdaq First North GM: CI B) is pleased to announce that Karina Sick Larsson has been appointed as Chief Human Resources Officer (CHRO) and will start her position on September 16, 2021. Karina will be responsible for the company's human resources function with a focus on organizational development.

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the first quarter.

An extraordinary general meeting of Cell Impact AB (Nasdaq First North GM: CI B) was held on August 9, 2021.

The shareholders of Cell Impact AB (Nasdaq First North GM: CI B), reg. no. 556576-6655, are hereby invited to participate in an extraordinary general meeting on Monday 9 August 2021.

The order is for development of flow plate tooling and flow plate prototype production and will be delivered duringthe third quarter of 2021. This order is a continuation of earlier established activities in Japan as part of the cooperation with NKC Japan.

Cell Impact AB (Nasdaq First North GM: CI B) is pleased to announce that Daniel Vallin has been appointed new Chief Operating Officer (COO) and will start his new position on August 16, 2021. He will succeed Tord Lätt, who will take over the role of Chief Project Manager (CPO) with responsibility for Cell Impact's automation development program.

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the first quarter.

Cell Impact AB's (Nasdaq First North GM: CI B) annual general meeting for the financial year 2020 was held on 22 April, 2021.

Located in the Minato-ku district in central Tokyo, Cell Impact Japan Inc.'s mission is to market and position Cell Impact in the growing Japanese hydrogen economy.

The shareholders of Cell Impact AB (publ), reg. no. 556576-6655, are hereby invited to participate in the annual general meeting to be held on Thursday, 22 April 2021.

Cell Impact AB (Nasdaq First North GM: CI B) has received an order worth MSEK 1.3 for serial production of bipolar flow plates from Beijing-based Nowogen Technology in China. The order is a continuation of the prototype order that Nowogen placed in September last year.

Cell Impact AB (Nasdaq First North GM: CI B) has received an order worth SEK 42 million from world-leading fuel cell supplier Plug Power Inc for a Cell Impact Forming™ production line and flow plates for delivery during 2021.

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the fourth quarter.

Cell Impact (Nasdaq First North Growth Market: CI B) has appointed Mr. Forrest Zhang as Country Manager in China. Mr. Zhang will be based in Shanghai and will begin his new position on May 3, 2021.

In 2019, Cell Impact (Nasdaq First North Growth Market: CI B) and Nakanishi Metal Works Co. Ltd (NKC)announced a Memorandum of Understanding (MoU, see press release 2019-08-29) aimed at exploring an international business development collaboration. On December 3, following a year-long feasibility study, NKC and Cell Impact jointly concluded that there were not enough mutual synergies to justify further deepening the cooperation. NKC will remain a valued potential partner in future business ventures.

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the third quarter.

Cell Impact AB (Nasdaq First North Growth Market: CI B) announces that the new production facility in Karlskoga, Brickegården, is now ready for production of flow plates. With a strong cash reserve, the company is now increasing the pace of positioning itself as a global volume supplier to the growing fuel cell industry.

The Board of Directors of Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") has, based on the authorization granted by the annual general meeting on April 16, 2020, resolved on a directed issue of 7,000,000 series B shares at a subscription price of SEK 25 per share (the "Share Issue"), which means that the Company raises SEK 175,000,000 before transaction costs. The subscription price in the share issue has been determined through an accelerated bookbuilding procedure, performed by Carnegie Investment Bank AB (publ) and Stockholm Corporate Finance AB, and corresponds to a discount of approximately 6.7 percent compared to the closing price on Nasdaq First North Growth Market as of October 6, 2020. Several Swedish and international institutional investors, e.g. BNP Paribas Energy Transition Fund, DNB Asset Management (including the funds DNB Miljøinvest, DNB Renewable Energy and DNB Disruptive Opportunities) and Cicero Fonder, participated in the Share Issue.

Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") hereby announces its intention to, based on the authorization granted by the annual general meeting held on April 16, 2020, execute a share issue of approximately 7 million series B shares in the Company directed to Swedish and international institutional investors (the "Share Issue"). The Company has retained Carnegie Investment Bank AB (publ) as Sole Global Coordinator and Sole Bookrunner and Stockholm Corporate Finance AB as Co-manager in connection with the Share Issue (together the "Managers"). The subscription price and the total number of new shares in the Share Issue will be determined through an accelerated bookbuilding procedure (the "Bookbuilding") led by the Managers and will commence immediately following the announcement of this press release.

Cell Impact AB (Nasdaq First North GM: CI B) has received an order worth 1.5 MSEK for prototype production of bipolar flow plates from Nowogen Technology. The order is a supplemental order to a previous tooling and development order that Cell Impact received in November 2018. Delivery is scheduled to begin in the fourth quarter of 2020 and be completed during the first quarter of 2021.

During the second quarter of 2020, Cell Impact AB (publ) will begin a move to larger factory premises in Karlskoga. The new location, which is close to the current premises, makes it possible to build a significantly larger production capacity to increase delivery volumes in line with a growing order book and future demand.

Cell Impact AB (publ) has recruited Tord Lätt to the company's management team in the role of COO (Chief Operating Officer). Tord is 53 years old and has a solid operational background with a primary focus on setting up and improving efficiency in industrial manufacturing. He will take up the position in December and will be responsible for developing and managing Cell Impact's operations.

Cell Impact AB (publ) has initiated a collaboration with RISE IVF AB on the next generation of production technology for the production of metal flow plates for hydrogen-fueled fuel cells. The project runs over six months and is jointly financed by Cell Impact and Vinnova.

Cell Impact AB (publ) and the Japanese industrial group Nakanishi Metal Works Co. Ltd. (NKC) deepens its cooperation by signing a Memorandum of Understanding (MoU) on international business development.

Cell Impact AB (publ) announces that the Board, with the support of the share issue authorization from the Annual General Meeting on April 11, 2019, today has resolved upon a directed share issue of series B shares with a value of approximately SEK 5 million. The share issue is directed to the Japanese industrial group Nakanishi Metal Works Co. Ltd. (NKC), which has entered into a subscription undertaking of approximately SEK 4.5 million, and Mr. Shigeru Nakagawa, Executive Officer, NKC New Business Division, who has entered into a subscription undertaking of approximately SEK 0.5 million.

Cell Impact AB (publ) has received a 3.4 MSEK development and technology validation order from Nakanishi Metal Works Co. Ltd (NKC) in Osaka, Japan. The order encompasses both a technical enhancement to our forming technology and a limited flow plate validation production run for a global leading automotive manufacturer.

Cell Impact AB (publ) has recruited Ms. Tingting Guan as its first local resource in China, starting in October. Tingting Guan has a doctorate in fuel cell systems from the Royal Institute of Technology in Stockholm, and she will be based in Hangzhou City, Zhejiang Province. 

The use of fuels cells is intensifying in Euorpe and Cell Impact AB (publ) has decided to expand its presence in this market. The company has therefore recruited Mr. Achim Zeiss to Cell Impact's management team as Area Manager Europe, effective January 8, 2018.